A Phase Ib, Open‐Label Study of Dalantercept, an Activin Receptor‐Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma

LESSONS LEARNED. Patients with hepatocellular carcinoma (HCC) often have limited therapeutic responses to the vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor sorafenib, which is standard of care in advanced HCC. Targeting the activin receptor‐like kinase 1 (ALK1) and VEGF pathway...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncologist
Main Authors: Abou‐Alfa, Ghassan K., Miksad, Rebecca A., Tejani, Mohamedtaki A., Williamson, Stephen, Gutierrez, Martin E., Olowokure, Olugbenga O., Sharma, Manish R., El Dika, Imane, Sherman, Matthew L., Pandya, Shuchi S.
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley & Sons, Inc. 2018
Fag:
Clinical Trial Results
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6369956/
https://ncbi.nlm.nih.gov/pubmed/30352941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0654
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker